[Ip-health] Drug quality problems for GSK and BMS

Baker, Brook b.baker at neu.edu
Wed Oct 27 07:05:40 PDT 2010


It's deeply ironic given Big Pharma's constant screel about poor quality
generic medicines and how we need increased IP enforcement and
anti-counterfeiting measures to address quality and safety concerns that its
own house is so out of order.  Not only is Big Pharma constantly pilloried
and fined for off-label drug promotion, hiding negative clinical trials, and
cheating on pricing, but it is also apparently engaged in foot-dragging and
cover-ups when quality-control issues arise at its own manufacturing
facilities.  

Maybe PhRMA (and the European Commission and the USTR) could explain how
ACTA's focus on IP enforcement would help address quality-related
malfeasance by its patent/data/trademark protected members.


Professor Brook K. Baker
Health GAP (Global Access Project)
Northeastern U. School of Law
Program on Human Rights and the Global Economy
400 Huntington Ave.
Boston, MA 02115 USA
Honorary Research Fellow, University of KwaZulu Natal, Durban, S. Africa
(w) 617-373-3217
(cell) 617-259-0760
(fax) 617-373-5056
b.baker at neu.edu






More information about the Ip-health mailing list